Журнал включен в российские и международные библиотечные и реферативные базы данных
РИНЦ (Россия)
Регистрационное агентство DOI (США)
Ulrichsweb (Ulrich’s Periodicals Director

On the question of antiviral therapy of a new coronavirus infection (COVID-19)

DOI: https://doi.org/10.29296/25879979-2023-01-04

V.V. Skvortsov, E.M. Skvortsova, A.N. Gorbach
Federal State Budgetary Educational Institution of Higher Education «Volgograd state medical university» of the ministry of health of the Russian Federation. e-mail: [email protected]

Coronavirus infection, or COVID-19 (COronaVIrus Disease 2019), is a new epidemic infectious disease that poses a danger to the population due to its high contagiousness and the development of complications that are unfavorable for the patient’s life, such as ARDS, respiratory and multiple organ failure. The virus has spread worldwide since its detection in Wuhan, Hubei Province, China on December 12, 2019. The World Health Organization (WHO) has declared it a pandemic. Based on the Decree of the Government of the Russian Federation, the new coronavirus COVID-19 (SARS-COV-2) is included in the list of diseases dangerous to society, along with polio and plague. The world community, united by a common goal – to combat the pandemic, is taking measures to actively immunize the entire population through vaccination. However, despite the availability of many vaccines, the number of cases and deaths remains high. As of December 19, 2021, there were 274 644 270 confirmed cases of coronavirus infection in the world and 5 368 822 deaths. Based on the above data, it becomes obvious that the reasonable use of antiviral therapy drugs is necessary for a favorable outcome of the disease of each patient. The review examines the main antiviral drugs proposed by WHO for the treatment of new coronavirus infection (COVID-19). Studies with statistically significant data are selected, which make it possible to fully judge the effectiveness and make it possible to make an adequate decision on the prescription of these drugs. Based on the data obtained from in vitro studies and clinical trials, the prospect of using the above drugs in the treatment of a new coronavirus infection, their effectiveness in clinical practice, as well as the feasibility of using and possible combinations of prescribing these drugs, which can be used to treat and prevent a new coronavirus infection, are considered. The article discusses the effectiveness of the following drugs: remdesvir, interferon, lopinavir and ritonavir, riamilovir, ribavirin, umifenovir, darunavir and cobicistat, favipiravir, chloroquine and hydroxychloroquine, ivermectin and intravenous immunoglobulins.To achieve the goals and objectives of the TB service, a significant role belongs to the average medical staff, where there is a division of functional responsibilities.

coronavirus infection
antiviral drugs

  1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf Dis. 2020;20(5):533–534.
  2. Registration certificate Gam-COVID-Vac Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus [accessed November 28, 2020] Address: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d494c688- 0bc6-4c30-9e81-23f043ceb43e&t=
  3. Kim SB, Huh K, Heo JY, et al. Interim Guidelines on Antiviral Therapy for COVID-19. Infect Chemother. 2020;52(2):281–304.
  4. Kupferschmidt K., Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science. 2020; 22. [cited 2020 Nov 29] Available from: https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
  5. Ahsan W, Javed S, Bratty MA, et al. Treatment of SARS-CoV-2: How far have we reached? Drug Disc Ther. 2020 May 6;14(2):67–72.
  6. Shchelkanov MJ, Kolobukhina LV, Burgasova OA, et al. COVID-19: ETIOLOGY, CLINIC, TREATMENT. Infection and immunity. 2020;10(3):421–445.
  7. Cantini F, Goletti D, Petrone L, et al. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. drugs. 2020;80(18):1929–1946.
  8. Meini S, Pagotto A, Longo B, et al. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. J Clinic Med. 2020;9(7):2050.
  9. McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020; 157:104859.
  10. Tsvetov V.M., Mirzaev K.B., Sychev D.A. Can riamilovir be used to prevent infection and treat COVID-19? Quality clinical practice. 2020;(4S):15–17.
  11. Wu Xiaoke et al. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. engineering. 2020;6(10).
  12. Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917–921
  13. Huang D, Yu H, Wang T, et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020 Jul 3:10.1002/jmv.26256.
  14. Matveev A.V., Kiselev Yu.Yu., Sychev D.A. Possibility and prospects for the use of favipiravir in patients with COVID-19. Quality clinical practice. 2020;(4S):106–114.
  15. Bartoli A, Gabrielli F, Alicandro T, et al. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerge Med. 2021;16(2):281–308.
  16. Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrobial Agents. 2020;55(5):105938.
  17. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrobial Agents. 2020;56(1):105949.
  18. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020; 34:101663.
  19. Funck-Brentano C, Nguyen LS, Salem JE. Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19 [retraction of: Lancet. 2020 May 22;]. Lancet. 2020;396(10245): e2-e3.
  20. Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021;236(4):2959-2975. doi:10.1002/jcp.30055
  21. Formiga FR, Leblanc R, de Souza Rebouças J, et al. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release. 2021; 329: 758–761. doi: 10.1016/j.jconrel.2020.10.009
  22. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222–3228.
  23. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. Emerge Microbes Infect. 2020;9(1):727–732. doi: 10.1080/22221751.2020.1746199.
  24. Kudlay D.; Svistunov A.; Satyshev O. COVID-19 Vaccines: An Updated Overview of Different Platforms. Bioengineering 2022, 9, 714. https://doi.org/10.3390/bioengineering9110714
  25. Kozlov V.A., Tikhonova E.P., Savchenko A.A., et al. Clinical immunology. A practical guide for infectious disease specialists. Krasnoyarsk: Polikor, 2021. 563 p. (in Russian). DOI:10.17513/np.518